Belite Bio, Inc American Depositary Shares

About Belite Bio, Inc American Depositary Shares

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biopharmaceutical company developing innovative therapeutics for degenerative retinal diseases and metabolic disorders with significant unmet medical needs. The company's lead candidate, tinlarebant, targets Geographic Atrophy (GA) and Stargardt disease type 1 (STGD1), addressing the late-stage dry form of age-related macular degeneration affecting millions globally. Belite Bio's pipeline also includes LBS-009, an oral small molecule compound designed to treat metabolic diseases including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes, and gout. With a focused approach on rare and prevalent diseases, Belite Bio represents a compelling investment opportunity in the biopharmaceutical sector. Track BLTE stock performance, clinical trial updates, and pipeline developments to make informed investment decisions.